165 related articles for article (PubMed ID: 1621751)
1. Loracarbef (LY163892) versus cefaclor in the treatment of bacterial skin and skin-structure infections in an adult population.
McCarty J; Ruoff GE; Jacobson KD
Am J Med; 1992 Jun; 92(6A):80S-85S. PubMed ID: 1621751
[TBL] [Abstract][Full Text] [Related]
2. Loracarbef (LY163892) versus cefaclor and norfloxacin in the treatment of uncomplicated pyelonephritis.
Hyslop DL; Bischoff W
Am J Med; 1992 Jun; 92(6A):86S-94S. PubMed ID: 1621752
[TBL] [Abstract][Full Text] [Related]
3. Loracarbef (LY163892) versus cefaclor in the treatment of acute bacterial bronchitis.
Dere WH; Farlow D; Therasse DG; Ruoff GE
Clin Ther; 1992; 14(1):41-53. PubMed ID: 1576625
[TBL] [Abstract][Full Text] [Related]
4. Loracarbef vs. cefaclor in pediatric skin and skin structure infections.
Hanfling MJ; Hausinger SA; Squires J
Pediatr Infect Dis J; 1992 Aug; 11(8 Suppl):S27-30. PubMed ID: 1513609
[TBL] [Abstract][Full Text] [Related]
5. Loracarbef versus cefaclor in the treatment of cystitis and asymptomatic bacteriuria.
Iravani A
Clin Ther; 1992; 14(1):54-63. PubMed ID: 1576626
[TBL] [Abstract][Full Text] [Related]
6. Loracarbef versus cefaclor in the treatment of urinary tract infections in women.
Iravani A
Antimicrob Agents Chemother; 1991 Apr; 35(4):750-2. PubMed ID: 2069382
[TBL] [Abstract][Full Text] [Related]
7. Antibiotic therapy for urinary tract infections.
Iravani A; Bischoff W
Am J Med; 1992 Jun; 92(6A):95S-100S. PubMed ID: 1621753
[TBL] [Abstract][Full Text] [Related]
8. Loracarbef versus penicillin VK in the treatment of streptococcal pharyngitis and tonsillitis in an adult population.
McCarty J
Am J Med; 1992 Jun; 92(6A):74S-79S. PubMed ID: 1621750
[TBL] [Abstract][Full Text] [Related]
9. The safety profile of loracarbef: clinical trials in respiratory, skin, and urinary tract infections.
Therasse DG
Am J Med; 1992 Jun; 92(6A):20S-25S. PubMed ID: 1621742
[TBL] [Abstract][Full Text] [Related]
10. Cefprozil versus cefaclor in the treatment of mild to moderate skin and skin-structure infections. The Cefprozil Multicenter Study Group.
Parish LC; Doyle CA; Durham SJ; Wilber RB
Clin Ther; 1992; 14(3):458-69. PubMed ID: 1638587
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of cefaclor AF in the treatment of skin and skin-structure infections.
Schupbach CW; Olovich KG; Dere WH
Clin Ther; 1992; 14(3):470-9. PubMed ID: 1638588
[TBL] [Abstract][Full Text] [Related]
12. Loracarbef (LY163892) versus amoxicillin/clavulanate in the treatment of acute bacterial exacerbations of chronic bronchitis.
Zeckel ML; Jacobson KD; Guerra FJ; Therasse DG; Farlow D
Clin Ther; 1992; 14(2):214-29. PubMed ID: 1611645
[TBL] [Abstract][Full Text] [Related]
13. A comparative study of the efficacy, safety and tolerability of azithromycin and cefaclor in the treatment of children with acute skin and/or soft tissue infections.
Montero L
J Antimicrob Chemother; 1996 Jun; 37 Suppl C():125-31. PubMed ID: 8818853
[TBL] [Abstract][Full Text] [Related]
14. Loracarbef versus penicillin VK in the treatment of streptococcal pharyngitis and tonsillitis in adults.
McCarty J; Hernon Y; Linn L; Therasse DG; Molina A; Bleile N
Clin Ther; 1992; 14(1):30-40. PubMed ID: 1576624
[TBL] [Abstract][Full Text] [Related]
15. Comparison of loracarbef (LY163892) versus amoxicillin in the treatment of bronchopneumonia and lobar pneumonia.
Müller O; Wettich K
Infection; 1992; 20(3):176-82. PubMed ID: 1463527
[TBL] [Abstract][Full Text] [Related]
16. Cefprozil versus cefaclor in the treatment of acute and uncomplicated urinary tract infections. Cefprozil Multicenter Study Group.
Iravani A; Doyle CA; Durham SJ; Wilber RB
Clin Ther; 1992; 14(2):314-26. PubMed ID: 1611652
[TBL] [Abstract][Full Text] [Related]
17. Loracarbef (LY163892) versus amoxicillin/clavulanate in bronchopneumonia and lobar pneumonia.
Hyslop DL; Jacobson K; Guerra FJ
Clin Ther; 1992; 14(2):254-67. PubMed ID: 1611648
[TBL] [Abstract][Full Text] [Related]
18. Loracarbef (LY163892) versus amoxicillin/clavulanate in the treatment of acute purulent bacterial bronchitis.
Dere WH; Farlow D; Therasse DG; Jacobson KD; Guerra FJ
Clin Ther; 1992; 14(2):166-77. PubMed ID: 1611641
[TBL] [Abstract][Full Text] [Related]
19. [Clinical evaluation of cefpodoxime proxetil in the treatment of skin and soft tissue infections. A double blind comparison of cefpodoxime proxetil and cefaclor].
Yura J; Shinagawa N; Mizuno A; Watanabe S; Ando M; Sakai K; Ueda T; Morimoto K; Nakamura T; Hashimoto I
Jpn J Antibiot; 1988 Oct; 41(10):1517-37. PubMed ID: 3060626
[TBL] [Abstract][Full Text] [Related]
20. Multinational multicenter controlled trial comparing ceftibuten with cefaclor for the treatment of acute otitis media. Members of the Ceftibuten Otitis Media International Study Group.
Blumer JL; Mclinn SE; Deabate CA; Kafetzis DA; Perrotta RJ; Salgado O
Pediatr Infect Dis J; 1995 Jul; 14(7 Suppl):S115-20. PubMed ID: 7567311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
